Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2) that causes glycosuria and lowers blood glucose levels regardless of insulin sensitivity and β-cell secretory function.
Dapagliflozin is associated with reductions in blood pressure and body weight and carries a low intrinsic risk of hypoglycaemia. SGLT2 inhibitors have also demonstrated cardiovascular (CV) and renal benefits.
Dapagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. This medication is also used in people with type 2 diabetes and heart disease to lower the risk of going to the hospital for heart failure. Dapagliflozin works by increasing the removal of sugar by your kidneys.
Dapagliflozin is also used to treat heart failure. It may help you live longer and lower your risk of going to the hospital for heart failure. Dapagliflozin works by increasing the removal of sodium by your kidneys.
Dapagliflozin 5mg & 10mg
MODE OF ACTION:
Sodium Glucose cotransporters (SGLTs) are proteins that occur primarily in the kidneys and play an important role in maintaining glucose balance in the blood. SGLT1 and SGLT2 are the two most known SGLTs of this family. SGLT2 is the major transport protein and promotes reabsorption from the glomerular filtration glucose back into circulation and is responsible for approximately 90% of the kidney’s glucose reabsorption. SGLT2 is mainly expressed in the kidneys on the epithelial cells lining the first segment of the proximal convoluted tubule. By inhibiting SGLT2, Flozimax (Dapagliflozin) prevent the kidneys’ reuptake of glucose from the glomerular filtrate and subsequently lower the glucose level in the blood and promote the excretion of glucose in the urine (glucosuria).
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction
To improve glycemic control :
Initial dose: 5 mg orally once a day
May increase to 10 mg orally once a day for additional glycemic control if lower dose has been tolerated
Maximum dose: 10 mg/day
To reduce the risk of hospitalization for heart failure: 10 mg orally
Once a day
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.